FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx Corp.; Proposed settlement reached with Abbott Laboratories and Geneva Pharmaceuticals, Inc.

0 Comments | M2 Presswire, March, 2000

M2 PRESSWIRE-17 March 2000-US FTC: FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx Corp.; Proposed settlement reached with Abbott Laboratories and Geneva Pharmaceuticals, Inc. (C)1994-2000 M2 COMMUNICATIONS LTD RDATE:16032000 * Complaints Charge Multi-Million-Dollar Arrangements Were Designed to Keep Generic Versions of Cardizem CD and Hytrin Off the Market The Federal Trade Commission today charged two drug makers, Hoechst Marion Roussel (now Aventis) and Andrx Corporation, with engaging in anticompetitive practices in violation of Section 5 of the FTC Act, alleging that Hoechst, the maker of Cardizem CD, a widely prescribed drug for treatment of...